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Background: Australia commenced human papillomavirus (HPV) vaccination in 2007, with a two-year catch-up to
the age of 26; catch-up cohorts are thus now entering their thirties. Plans for monitoring vaccine impact involve
pre- and post-vaccination assessment of cervical HPV DNA in the general population and in high grade abnormalities.
Although HPV serology is less sensitive than DNA genotyping, it assesses lifetime exposure and may be easier to
measure in the general population. However, benchmark pre-vaccination seroprevalence of vaccine-included types in
unvaccinated women with high grade abnormalities has not previously been reported.
Methods: We assessed seroprevalence for HPV16/18 from a population-based sample of 3,729 women with normal
cytology and 971 women with confirmed high grade abnormalities (CIN2/3), aged 30–64 years, unvaccinated, and
recruited in New South Wales in 2006–2010. We examined the variation in HPV16/18 seropositivity by age and in
relation to a range of reproductive and behavioural characteristics in the subgroup of normal cytology women with
no recent history of high grade cervical disease.
Results: The HPV 16, 18 and combined seroprevalence was 19%, 7% and 24% among women with normal cytology,
and 39%, 13% and 44% among women with CIN2/3, respectively. For both groups, HPV16/18 seroprevalence was
highest at age 30–39 years and decreased with age. In multivariable analysis for women with normal cytology, HPV16
and HPV18 seropositivity were each associated with the number of lifetime sexual partners (p-trend <0.001 and 0.052,
respectively) and for HPV16 this was also associated with age (p-trend <0.001) and prior diagnosis of Chlamydia
(adjusted OR 1.89, 95% CI 1.27-2.80).
Conclusions: The findings of this study inform pre-vaccination estimates of HPV seropositivity in women with normal
cytology and women with high grade abnormalities. Almost a quarter of unvaccinated women aged over 30 years with
normal cytology, and more than 40% of those with CIN2/3, had seroconverted to HPV 16 or 18. These findings provide
a potential additional benchmark for assessing the effects of HPV vaccination.
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Human papillomavirus (HPV) types 16 and 18 are the
most frequent oncogenic HPV types detected in invasive
cervical cancers and precancerous cervical intraepithelial
neoplasia grade 3 (CIN3) worldwide [1]. Australia was
one of the first countries internationally to initiate a
publicly-funded National HPV Vaccination Program,
which commenced in April 2007. The program involves
the quadrivalent vaccine (Gardasil™, Merck, Whitehouse
Station, NJ, USA) which protects against infection with
the oncogenic types HPV 16 and 18, and also types 6
and 11, which are implicated in the development of the
majority of anogenital warts. The program involves rou-
tine vaccination of 12–13 year old girls at school, and
until 2009 also involved a school, General Practitioners
and community “catch-up phase” for women aged up to
26 years. Three-dose coverage rates in the first years of
the program varied from 73% in 12–13 year old girls to
~30% in 20–26 year old women [2]. In 2013, the pro-
gram was extended to boys. Early indications of the
effects of the National HPV Vaccination Program have
already been observed in vaccinated young cohorts–
these include a decline in the prevalence of cervical
HPV DNA for vaccine-included types in women aged
18–24 years [3], substantial declines in the incidence
and prevalence of high-grade abnormalities in women
up to 25 years old [4,5] and a reduction in the risk of
high grade cervical abnormalities in women who com-
pleted the vaccine series at the ages of 11–27 [6]. At
present, as initial vaccination cohorts are entering their
thirties, the effects of vaccination in women over 30 years
old can now be evaluated.
HPV surveillance is an important mechanism of mon-
itoring HPV prevalence at the population level, to
assess the potential effects of cross-protection against
non-vaccine-included types, and to exclude potential
type-replacement of the vaccine-included types. HPV
genotyping of normal cervical smears and for those with
high grade abnormalities pre- and post-vaccination, has
been proposed as part of such a program in Australia [7]
and more generally [8], to be able to monitor vaccine
effectiveness between these separate groups. An additional
or alternative (if resources are limited) monitoring tool to
genotyping would be HPV seroprevalence. The presence of
HPV DNA is a sensitive measure of current infection and
approximately 90% of cervical HPV infections are cleared
after two years of observation [9]. There is evidence that
antibody levels to HPV infection are stable over more than
4 years of follow-up [10] and can be used as markers of
past infection. However, only 54-70% [11-13] of women in-
fected with HPV-16/18 are thought to seroconvert after
natural infection and therefore serotyping is less sensitive
than genotyping. Blood samples for serology can be ob-
tained more readily and from a wide range of populationgroups (for example as residual specimens collected for
other purposes) and thus serology offers logistical advan-
tages compared to the collection of cervical samples for
genotyping. Using repeat cross-sectional surveys, before
and after vaccination, serology has the potential to comple-
ment other methods in monitoring vaccination impact.
For serology-based surveillance, benchmark data on
seroprevalence in unvaccinated women are required. Large
studies assessing age-stratified, pre-vaccination seropreva-
lence data in women with and without cervical dysplasia
are sparse. In Australia, we identified only one study [14],
using a convenience sample of men and women aged up to
69 years which was limited by lack of information on
cytology/histological status and on potential risk factors for
HPV exposure, which might be important for monitoring
outcomes in higher risk groups. More generally, there are
only a few large studies internationally that have examined
factors associated with HPV16 and 18 seropositivity
[15,16], none of which were conducted in Australia. There-
fore the aims of the current analysis were (1) to quantify
HPV16, 18 and combined 16/18 seroprevalence by age
among unvaccinated women over 30 years of age with a
normal cytology smear or with histologically-confirmed
CIN 2/3 (the ‘pre-vaccination benchmark’ data); and (2) to
investigate the relationship between detection of HPV16 or
18 seropositivity and a range of sexual and behavioural
characteristics.
Methods
Study design and recruitment
Data and samples for this analysis have been obtained
from the Cervical Health Study, a large population-based
case–control study conducted in New South Wales
(NSW), which was designed primarily to assess the role of
exogenous hormonal co-factors in the development of
cervical pre-cancerous lesions. Recruitment was con-
ducted between December 2006 and July 2011 in women
aged 20–64 years, via invitation letters issued from the
centralised NSW Pap Test Register (PTR) which records
all cervical cytology and histology test results, as well
as past disease, except for those associated with <1% of
women who opt-out. General Practices were first
approached to consent for invitations to be sent to
women under their care. Invitation letters were then is-
sued to eligible women with a new record of a cytological/
histological test. Cases had a new registry record of a low
or high grade precancerous cytological or histological ab-
normality while controls had a new record of a normal
cytological result in the same week as the abnormal smear
for the matched case. Screening histories for up to 5 years
prior to study participation were obtained from the PTR.
Following informed consent, participants completed a
self-administered questionnaire assessing demographic
and medical details, and lifestyle factors. In the first phase
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blood sample (women aged 30–64 years only). The
Cervical Health Study commenced prior to the vaccin-
ation catch-up program implementation (covering ages of
12–26 years) but continued throughout the duration of
the program. Therefore, vaccination status was confirmed
by self-report.
For the current analysis, HPV16/18 seropositivity was
investigated in women with histologically confirmed
CIN2/3 and in women with normal cytology. Data has
been obtained from the Cervical Health Study, however,
analyses were restricted to women aged 30 years of age
and above, who provided both a questionnaire and a
blood sample. Women who indicated in their question-
naire that they had been vaccinated against HPV were
excluded (n = 4). Analyses were conducted on 4700
women including 3,729 women with normal cytology
and 971 with histologically confirmed CIN2/3.
Sample processing and serological evaluation
Blood samples were collected by phlebotomists from
December 2006 to August 2010 at several laboratories in
NSW. Blood was collected in serum separating tubes,
left to clot at room temperature for 30 mins, centrifuged,
aliquoted into 2 ml aliquots within 48 hours of collec-
tion and stored at −80°C until analysis. Serum samples
were pre-randomised by study number prior to aliquoting
to ELISA plates. 210 samples were analysed in duplicate.
Samples were tested ‘blind’ at the University of Queens-
land for circulating antibodies to the HPV16/18 late cap-
sid protein L1 using a HPV-neutralising assay based on
pseudoviruses carrying a secreted alkaline phosphatase re-
porter gene as described by Pastrana et al. [17]. A sample
with an optical density reading below 50% of the negative
control was considered HPV seropositive. Separate assays
were conducted for HPV16 and 18. Blinded repeat testing
was conducted for a random 7% of samples.
Data analysis
The seroprevalences of HPV16, HPV18 and HPV16/18
combined, in the two groups of women were estimated
and 95% confidence intervals (CIs) were calculated using
the exact binomial method. Subjects were categorised
into age groups (30–39, 40–49, 50–59 and 60–64 years).
Factors associated with seropositivity to HPV16 only or
HPV18 only were investigated in a subset of 3,462 of the
control women with an index negative smear and a history
of normal cytology in the last five years. To evaluate the
characteristics associated with each HPV type separately,
women (N = 267) who were seropositive for both HPV
types were excluded from these analyses. In doing so we
followed the same analytical strategy as a major prior
National Cancer Institute (NCI) USA study [12]. As in the
NCI study, we restricted our analysis to women who werepositive only for the single HPV type of interest. Similar
analysis was not conducted in women with CIN2/3,
because separate risk factors exist for progression of estab-
lished HPV infection to high grade disease, which include
use of oral contraceptives, current use of tobacco, parity
and age at first term pregnancy [18-21], making the inter-
pretation of any associations between these risk factors
and HPV seropositivity in women with confirmed high
grade disease complex. Unconditional logistic regression
was used to estimate odds ratios (ORs) and 95% CIs for
each potential factor adjusting for the following variables;
age group, smoking, number of children, age at sexual
debut, number of partners in the last 5 years, number of
partners before the last 5 years, number of lifetime partners,
and diagnosis of Chlamydia trachomatis (C.trachomatis).
Associations between seropositivity and use of hormone
contraceptives or use hormone replacement therapy were
not assessed because the numbers of HPV16 or HPV18
seropositive users (never, past and current) were too low to
provide sufficient statistical power for sub-group analysis to
be conducted. A complete case approach was adopted for
the analysis. Dose response associations (p-trend) were
examined for ordinal variables which could be treated as
continuous assuming a linear trend in the models and p-
nominal values were estimated for all variables. All analyses
were conducted using SAS software, version 9.3.
Ethical approval
The study was approved in 2004 by the Cancer Institute
NSW Population Ethics Committee; reference number
Ref 2004/05/073.
Results
HPV 16 and 18 seroprevalence
The overall HPV 16, 18 and combined HPV16 or 18 sero-
prevalence was 19.4% (723/3,729), 7.1% (266/3,729) and
23.5% (875/3,729) among women with normal cytology,
and 38.5% (374/971), 12.7% (123/971) and 43.8% (425/971)
among women with CIN2/3, respectively. Table 1 and
Figure 1 present the seroprevalence results by age group.
In both groups and for both HPV16 and HPV18, preva-
lence decreased with age; in women aged 30–39 years with
normal cytology the combined seroprevalence was 33%
and in women in the same age group with CIN2/3, it was
over 55% (Table 1).
Factors associated with HPV16 seropositivity in women
with normal cytology
Table 2 presents the odds ratios for factors potentially
associated with seropositivity. HPV16 seropositivity was
significantly associated with younger age (p-trend <0.001);
in the multivariable model, the odds of detecting anti-
HPV16 antibodies in women 60–64 years of age was close
to half that of women 30–39 years of age (OR 0.53, 95%
Table 1 Seroprevalence of HPV16 and 18 in women with CIN 2/3 and women with normal cytology, by age group
Age,
years
CIN2/
3 (No)
Normal
cytology
(No)
HPV16 seroprevalence % (95% CI) HPV18 seroprevalence % (95% CI) HPV16 or 18 seroprevalence % (95% CI)
CIN 2/3 Normal cytoa CIN 2/3 Normal cytoa CIN 2/3 Normal cytoa
all 971 3729
30-39 348 708 50.6 (45.2-55.9) 28.1 (24.8-31.6) 14.4 (10.9-18.5) 10.6 (8.4-13.1) 55.2 (49.8-60.5) 32.6 (29.2-36.2)
40-49 230 517 35.2 (29.0-41.8) 23.6 (20.0-27.5) 13.9 (9.7-19.1) 7.7 (5.6-10.4) 42.6 (36.1-49.3) 27.7 (23.8-31.7)
50-59 300 1945 31.7 (26.4-37.3) 17.4 (8.8-14.2) 11.7 (8.3-15.8) 6.7 (5.6-7.9) 36.3 (42.1-60.9) 21.8 (20.0-23.7)
60-64 93 559 23.7 (15.5-33.6) 11.3 (8.8-14.2) 6.5 (2.4-13.5) 3.8 (2.3-5.7) 28.0 (19.1-38.2) 13.6 (10.9-16.7)
aCyto: cytology.
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number of lifetime partners (p-trend < 0.001). The odds of
detecting antibodies against HPV16 were over six-fold
higher in women with three or more sexual partners in
their lifetime than women with only one partner (OR 6.50,
95% CI: 4.53-9.34), in the fully adjusted model. Seropositiv-
ity was also associated with the number of partners before
the last 5 years (p-trend <0.001). In addition, ever having a
diagnosis of C.trachomatis was associated with an in-
creased risk of being HPV16 seropositive (OR 1.89, 95%
CI: 1.27-2.80). After multivariable adjustment no other
significant associations were seen.Figure 1 Seroprevalence of (A) HPV16 and (B) HPV18, in women with
[Data from Newall et al. [14] showing Australian, female population seropreFactors associated with HPV18 seropositivity in women
with normal cytology
Results for HPV18 are presented in Table 3. Having an
increasing number of sexual partners in a lifetime was
associated with an increased risk of being HPV18 sero-
positive (p-trend = 0.052; p-nominal <0.001), and women
with 3 or more lifetime partners had 6-fold increased
odds (OR 6.16; 95% CI: 2.89-13.13) in comparison to
women with one lifetime partner. Also, seropositivity
was associated with the number of partners before the
last 5 years (p-trend = 0.032). No other associations were
observed in the fully adjusted analysis.CIN 2/3 and women with normal cytology, by age group.
valence are also shown for comparison].
Table 2 Odds ratios for HPV16 seropositivity in women with normal cytology
Characteristic Anti-HPV16 Atba Unadjusted
OR (95% CI)
OR1b (95% CI) OR2c (95% CI) p-trend/
p-nominald-ve +ve
All women 2659 522
Age
30-39 410 122 Ref. n/a Ref.
40-49 345 93 0.90 (0.66-1.22) n/a 0.93 (0.67-1.28) <0.001
50-59 1469 259 0.59 (0.46-0.75) n/a 0.71 (0.54-0.92) 0.003
60-64 435 48 0.37 (0.26-0.53) n/a 0.53 (0.36-0.78)
Smoking
Never 1626 241 Ref. Ref. Ref.
Past 781 206 1.77 (1.44-2.18) 1.76 (1.43-2.16) 1.18 (0.95-1.48) n/ae
Current 252 75 2.00 (1.49-2.68) 1.91 (1.43-2.57) 1.16 (0.85-1.60) 0.310
No of children
0 245 81 Ref. Ref. Ref.
1 296 81 0.83 (0.58-1.18) 0.82 (0.58-1.17) 0.91 (0.63-1.31) 0.146
2 1087 204 0.57 (0.43-0.76) 0.60 (0.45-0.81) 0.81 (0.59-1.10) 0.823
≥3 1031 156 0.46 (0.34-0.62) 0.51 (0.38-0.70) 0.78 (0.56-1.07)
Age at sexual debut
≥18 1609 255 Ref. Ref. Ref.
17 392 94 1.51 (1.16-1.96) 1.44 (1.11-1.87) 0.95 (0.72-1.26)
16 370 82 1.40 (1.06-1.84) 1.29 (0.98-1.70) 0.79 (0.59-1.07) 0.315
15 132 45 2.15 (1.50-3.09) 1.89 (1.31-2.74) 1.06 (0.71-1.57) 0.408
<15 84 32 2.40 (1.57-3.69) 2.13 (1.38-3.29) 1.00 (0.63-1.58)
Prefer not to answer 72 14 1.23 (0.68-2.21) 1.24 (0.69-2.25) 0.56 (0.29-1.12)
C. trachomatis diagnosis
No 2545 467 Ref. Ref. Ref.
Yes 87 46 2.88 (1.99-4.17) 2.73 (1.88-3.97) 1.89 (1.27-2.80) n/ae
Prefer not to answer 27 9 1.81 (0.85-3.88) 1.73 (0.80-3.72) 1.21 (0.55-2.66) 0.006
Partners in last 5y
0-1 2457 427 Ref. Ref. Ref.
2 86 48 3.20 (2.22-4.63) 2.93 (2.02-4.25) 2.18 (1.48-3.21) 0.165
≥3 76 39 2.95 (1.98-4.39) 2.47 (1.64-3.71) 1.49 (0.97-2.29) <0.001
Prefer not to answer 40 8 1.15 (0.53-2.47) 1.23 (0.57-2.65) 0.77 (0.33-1.80)
Partners before the last 5y
0-1 1240 74 Ref. Ref. Ref.
2 249 45 3.12 (2.11-4.62) 2.99 (2.01-4.44) 2.92 (1.96-4.36) <0.001
≥3 934 325 5.89 (4.51-7.69) 5.45 (4.17-7.13) 4.65 (3.48-6.22) <0.001
Prefer not to answer 236 78 5.79 (4.07-8.23) 5.47 (3.86-7.76) 5.88 (3.95-8.76)
Lifetime No sex partners
1 934 38 Ref. Ref. Ref.
2 337 35 2.55 (1.59-4.11) 2.46 (1.52-3.96) 2.35 (1.45-3.80) <0.001
≥3 1166 374 7.89 (5.59-11.14) 7.30 (5.16-10.33) 6.50 (4.53-9.34) <0.001
Prefer not to answer 222 75 8.34 (5.50-12.65) 8.08 (5.32-12.27) 8.08 (5.14-12.69)
aAnt: antibodies;
bORs are adjusted for age only.
cORs are adjusted for age, smoking, No of children, age at sexual debut, C.trachomatis diagnosis, partners in the last 5 years and partners before the last 5 years
with the exception of the OR for lifetime No sex partners which were not adjusted for partners in last 5 years or partners before the last 5 years due to
multi-collinearity between these three variables.
dp-values are for OR2.
en/a: not applicable.
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Table 3 Odds ratios for HPV18 seropositivity in women with normal cytology
Characteristic Anti-HPV18 Atba Unadjusted
OR (95% CI)
OR1b (95% CI) OR2c (95% CI) p-trend/
p-nominald-ve +ve
All women 3053 128
Age
30-39 510 22 Ref. n/a Ref.
40-49 421 17 0.94 (0.49-1.79) n/a 0.92 (0.48-1.78) 0.893
50-59 1651 77 1.08 (0.67-1.79) n/a 1.23 (0.74-2.03) 0.378
60-64 471 12 0.59 (0.29-1.21) n/a 0.76 (0.36-1.59)
Smoking
Never 1809 58 Ref. Ref. Ref.
Past 928 59 1.98 (1.37-2.88) 1.99 (1.37-2.89) 1.40 (0.94-2.07) n/ae
Current 316 11 1.09 (0.56-2.09) 1.07 (0.56-2.07) 0.70 (0.36-1.39) 0.065
No of children
0 311 15 Ref. Ref. Ref.
1 359 18 1.04 (0.51-2.10) 1.06 (0.52-2.14) 1.13 (0.55-2.34) 0.352
2 1229 62 1.04 (0.59-1.86) 1.06 (0.59-1.89) 1.39 (0.75-2.55) 0.174
≥3 1154 33 0.59 (0.32-1.10) 0.60 (0.32-1.13) 0.86 (0.44-1.66)
Age at sexual debut
≥18 1800 64 Ref. Ref. Ref.
17 463 23 1.40 (0.86-2.27) 1.35 (0.83-2.20) 0.99 (0.60-1.64) 0.941
16 428 24 1.58 (0.97-2.55) 1.53 (0.94-2.48) 1.02 (0.61-1.71) 0.605
15 171 6 0.99 (0.42-2.31) 0.96 (0.41-2.25) 0.63 (0.26-1.52)
<15 108 8 2.08 (0.97-4.46) 2.02 (0.94-4.34) 1.25 (0.56-2.78)
Prefer not to answer 83 3 1.02 (0.31-3.30) 1.01 (0.31-3.28) 0.39 (0.11-1.42)
C. trachomatis diagnosis
No 2898 114 Ref. Ref. Ref.
Yes 123 10 2.07 (1.06-4.05) 2.02 (1.03-3.97) 1.58 (0.79-3.17) n/ae
Prefer not to answer 32 4 3.18 (1.11-9.14) 3.15 (1.09-9.09) 2.16 (0.71-6.55) 0.187
Partners in last 5y
0-1 2770 114 Ref. Ref. Ref.
2 129 5 0.94 (0.38-2.35) 0.92 (0.37-2.29) 0.73 (0.29-1.85) 0.939
≥3 107 8 1.82 (0.86-3.82) 1.83 (0.86-3.92) 1.34 (0.61-2.95) 0.499
Prefer not to answer 47 1 0.52 (0.07-3.78) 0.52 (0.07-3.82) 0.30 (0.04-2.36)
Partners before the last 5y
0-1 1295 19 Ref. Ref. Ref.
2 280 14 3.42 (1.70-6.91) 3.32 (1.64-6.70) 3.14 (1.55-6.39) 0.032
≥3 1189 70 4.07 (2.44-6.80) 3.95 (2.35-6.61) 3.49 (2.00-6.06) <0.001
Prefer not to answer 289 25 6.11 (3.30-11.31) 5.83 (3.17-10.74) 6.98 (3.56-13.68)
Lifetime No sex partners
1 964 8 Ref. Ref. Ref.
2 361 11 3.67 (1.46-9.20) 3.64 (1.45-9.14) 3.45 (1.37-8.65) 0.052
≥3 1455 85 7.02 (3.39-4.56) 6.92 (3.32-14.40) 6.16 (2.89-13.13) <0.001
Prefer not to answer 273 24 10.63 (4.72-23.92) 10.43 (4.63-23.50) 11.12 (4.72-26.17)
aAnt: antibodies;
bORs are adjusted for age only.
cORs are adjusted for age, smoking, No of children, age at sexual debut, C.trachomatis diagnosis, partners in the last 5 years and partners before the last 5 years
with the exception of the ORs for lifetime No sex partners which were not adjusted for partners in the last 5 years or partners before the last 5 years due to
multi-collinearity between these three variables.
dp-values are for OR2
en/a: not applicable
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To our knowledge this is the first study to provide
population-based benchmarking information on HPV16
and 18 serology in unvaccinated women with normal cy-
tology and with high grade abnormalities in Australia. The
seroprevalence measurements obtained in unvaccinated
women in this study indicate high levels of exposure to
HPV 16/18, most notably in women in their thirties. As
expected, seroprevalence for both HPV types was higher
in women with CIN 2/3 than those with normal cytology.
The highest seroprevalence in both groups was observed
in 30–39 year old women and it decreased with age. We
also found that the number of lifetime sexual partners was
associated with the detection of HPV16 and 18 antibodies
in the subgroup of women with a history of normal cy-
tology and that this association was due to past exposure.
In this subgroup, younger age and ever having a diagnosis
of C.trachomatis were significantly associated with HPV16
seropositivity.
Population cervical HPV DNA prevalence for oncogenic
types tends to peak earlier than seroprevalence, with the
DNA prevalence pattern reflecting a high risk of current
infection around the time that young women first initiate
sexual activity. Age-specific patterns of infection for
whole-of-population cervical HPV DNA prevalence tend
to be comparable but slightly higher than those for
women in the population with normal cytology (i.e. ex-
cluding the relatively small group with a cytological pre-
diction of an abnormality), and most studies of population
DNA prevalence, including the IARC HPV surveys [22],
report their findings for women with normal cytology. A
systematic review of the worldwide literature has demon-
strated that the highest oncogenic cervical HPV DNA
prevalence is observed in women aged <25 years, with de-
creasing prevalence in older age groups in most geograph-
ical regions [23]. In a pre-vaccination Australian survey,
the peak population cervical HPV16 or 18 DNA preva-
lence in both Indigenous and non-Indigenous women was
observed in women under 21 years of age [24].
In terms of seroprevalence, our finding of decreasing
HPV16 and 18 seroprevalence with increasing age in
unvaccinated mid-adult and older women with normal
cytology is consistent with other Australian data, although,
studies done with different assays and at different labora-
tories complicate comparisons across studies. For the age
groups for which comparative data were available, we ob-
served a close correspondence between our findings and
the general population findings of Newall et al. [14], which
included females in their teens and twenties, and identi-
fied a peak seroprevalence of HPV16 and 18 in the 30–39
year old age group. Our findings are also broadly consist-
ent with previously published data from other settings. A
review of population seroprevalence in low-resource
countries [22] reported a tendency of HPV16 and 18seroprevalence to increase from young to middle age and
then decline or stabilize thereafter. A global review of 117
studies [25] reported peaks in seroprevalence for HPV16
in women 25–40 years old and for HPV18 in women 35–
55 years old. Taken together with other studies our find-
ings are consistent with the probability that, prior to
vaccination, the peak for both HPV16 and 18 seropreva-
lence in the general population occurred at an older age
than for DNA prevalence for these types. These differ-
ences between the peak ages for current infections and for
seroprevalence are likely to reflect, in part, the cumulative
nature of seroprevalence as a measure of exposure – rates
in women in their thirties may reflect exposure after initi-
ation of sexual activities in their teenage years but also
through their twenties.
The underlying reasons for declining seroprevalence of
these HPV types at older ages are uncertain, but may in-
clude waning of naturally-acquired immunity over time
and/or changes in the risk of HPV infection within succes-
sive birth cohorts over the past several decades. Waning
anti-HPV16 antibody levels could in part explain our
observation of a decreasing prevalence with age [15]
although one study has suggested that HPV16 antibody
titres do not decrease with age [26]. Changes in exposure
in younger versus older birth cohorts seems a plausible
alternate or additional explanation [26], since younger age
at first sexual encounter and a higher number of sexual
partners are observed in younger cohorts in many high
resource countries [27].
We also examined risk factors for seropositivity in
women with a history of normal cytology over the last five
years, a subgroup less likely to be experiencing a current
HPV infection (which may lead to abnormal cytology).
The lifetime number of sexual partners and the number of
past partners were associated with the detection of
HPV16 and 18 antibodies. These findings are consistent
with previous reports from other settings [12,15,28-30]
and reflect cumulative past exposure to HPV, and possibly
increased frequency and more sustained HPV exposure
over time, which could favour seroconversion and thus
antibody detection. We also observed an association be-
tween women reporting a past C. trachomatis infection
and HPV16 seropositivity; having a previous C. trachoma-
tis infection may be a marker of additional risk beyond
that associated with the lifetime number of partners per
se, which could occur, for example, if it acted as a marker
for contact with higher risk partners. A similar association
has been observed previously between herpes simplex
virus-2 seroprevalence and HPV seropositivity [31]. No
evidence has been identified in large scale pooled analyses
of the worldwide data for a possible alternate explanation
that sexually transmitted infections act as a co-factor in
HPV persistence and/or progression. We also found that
increasing age was associated with lower odds of detecting
Velentzis et al. BMC Infectious Diseases  (2014) 14:3861 Page 8 of 10anti-HPV16 antibodies, but interestingly, the association
was not confirmed for HPV18 antibodies. Taken together,
these findings suggest that in our study, cohort effects
impacting on the lifetime number of partners may be
sufficient to explain the decreasing seroprevalence for
HPV18, but not for HPV16, at older ages.
A number of studies have reported on pre-vaccination
cervical HPV DNA prevalence in women with confirmed
high grade abnormalities in various populations. Our recent
study in New Zealand reported that the HPV16/18 DNA
prevalence in women with CIN2/3, peaked among women
20–29 years of age and decreased with older age [32], indi-
cating that high grade abnormalities in younger women in
the pre-vaccination era were more likely to have been
caused by the vaccine-included HPV types. Broadly similar
observations for women with cervical intraepithelial neo-
plasia have been reported in other countries [33-36]. In
contrast to the extensive literature for cervical HPV DNA
studies, we identified few studies of oncogenic HPV
seroprevalence in a population-based sample of women
presenting with histologically-confirmed high grade abnor-
malities. A study in Costa Rica examined HPV seropreva-
lence in women with high grade abnormalities but
participants were HPV16 or 18 DNA positive and thus the
findings cannot be directly compared to the current study
[12]. Among women with CIN2 recruited in a US trial, the
peak seroprevalence for HPV16 and 18 was observed for
the age group 20–25 years decreasing in older age groups
[37], although the median age of participants was 27 years
and thus limited comparative data are available for women
aged over thirty years. Therefore, although directly compar-
able results from other studies are not available, our finding
of an overall 44% HPV16/18 seroprevalence in women over
30 years old with high grade abnormalities is broadly
consistent with studies showing that about half of all HPV-
positive histologically confirmed high grade lesions are
associated with the presence of cervical HPV16/18 DNA
(as opposed to other oncogenic types), but this proportion
decreases in women over 30 years of age [32,38].
This study is subject to potential limitations. Partici-
pants were recruited from the NSW Pap Test Register
and therefore results may not be representative of the gen-
eral female population of NSW. Although few women
opt-out of the register, recent national figures indicate that
only 57% of women 20–69 years of age attended cervical
screening [39]. Furthermore, due to the unavailability of
cervical DNA samples, it was not possible to carry out
HPV genotyping; it is therefore unknown whether study
participants had prevalent HPV cervical infections of the
same genotype. However, this study has a number of
strengths including the relatively large sample size, the
availability of risk factor and demographic information,
the 5 year cervical screening history for participants, the
concurrent assessment of HPV16 and 18 seropositivity inwomen with CIN 2/3 and women with normal cytology
and recruitment from a single source.
Conclusion
By providing information on seroprevalence of HPV types
16 and 18 in unvaccinated women with normal cytology
and with high grade abnormalities, this study establishes
the possibility of using serology for monitoring changes in
population level exposure over time. However, as HPV
seropositivity due to natural infection is based on repeated
and persistent exposure rather than incident infection, ser-
ology results have to be interpreted with caution; further-
more vaccine exposure will lead to complex serological
patterns for vaccine-included types in cohorts offered
vaccination. We also note that when used in combination
with individual-level information on vaccination status
(which is available, in principle, for accredited research
purposes, through Australia’s National HPV Vaccination
Register), serology could be used to measure natural HPV
16 and 18 exposure in populations where vaccinated
women mostly received the vaccine at a young enough
age to be protected from HPV 16 and 18 infection. This is
the expectation for Australia, in years to come, given that
successive cohorts of 12–13 year old schoolgirls will
receive the vaccine through the vaccination program and
given that the government no longer subsidises the vac-
cination of older women. In such populations, vaccinated
women can be reasonably assumed to be unexposed to
natural infection with HPV 16 and 18 because of the pro-
tection provided by the vaccine. Serology may then have a
role to estimate HPV 16/18 exposure in the unvaccinated
remainder of the population.
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